Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Reasons for failure to identify positive sentinel nodes in breast cancer patients with significant nodal involvement.

de Kanter AY, Menke-Pluijmers MB, Henzen-Logmans SC, van Geel AN, van Eijck CJ, Wiggers T, Eggermont AM.

Eur J Surg Oncol. 2006 Jun;32(5):498-501. Epub 2006 Apr 3.

PMID:
16580810
2.

Discrepancy between second and first opinion in surgical oncological patients.

Mellink WA, Henzen-Logmans SC, Bongaerts AH, Ooijen BV, Rodenburg CJ, Wiggers TH.

Eur J Surg Oncol. 2006 Feb;32(1):108-12. Epub 2005 Nov 21.

PMID:
16303280
3.

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.

Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JH, Klijn JG, Look MP, Foekens JA, Stoter G, Berns EM.

Br J Cancer. 2001 Nov 2;85(9):1359-67.

4.

Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue.

van der Flier S, van der Kwast TH, Claassen CJ, Timmermans M, Brinkman A, Henzen-Logmans SC, Foekens JA, Dorssers LC.

Int J Biol Markers. 2001 Jul-Sep;16(3):172-8.

PMID:
11605729
5.

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG.

N Engl J Med. 2001 Jul 19;345(3):159-64.

6.

Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control.

de Kanter AY, van Geel AN, Paul MA, van Eijck CH, Henzen-Logmans SC, Kruyt RH, Krenning EP, Eggermont AM, Wiggers T.

Eur J Surg Oncol. 2000 Nov;26(7):652-6.

PMID:
11078611
7.

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.

Cancer Res. 2000 Apr 15;60(8):2155-62.

8.

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

Cancer Res. 2000 Feb 1;60(3):636-43.

9.

[Second Opinion Consult Clinic for Surgical Oncology in the Daniel den Hoed Clinic: analysis of the first 245 patients].

Mellink WA, Henzen-Logmans SC, Bongaerts AH, Pruyn JF, van Geel AN, Wiggers T.

Ned Tijdschr Geneeskd. 1999 Dec 4;143(49):2471-5. Dutch.

PMID:
10608986
10.

Immunocytochemical detection of prognostic markers in breast cancer; technical considerations.

Kuenen-Boumeester V, Timmermans AM, De Bruijn EM, Henzen-Logmans SC.

Cytopathology. 1999 Oct;10(5):308-16.

PMID:
10588349
11.

Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast.

Kuenen-Boumeester V, Henzen-Logmans SC, Timmermans MM, van Staveren IL, van Geel A, Peeterse HJ, Bonnema J, Berns EM.

J Pathol. 1999 Oct;189(2):169-75.

PMID:
10547570
12.

Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro.

Sieuwerts AM, Klijn JG, Henzen-Logmans SC, Foekens JA.

Breast Cancer Res Treat. 1999 May;55(1):9-20.

PMID:
10472775
13.

Prognostic value of CD44 variant expression in primary breast cancer.

Foekens JA, Dall P, Klijn JG, Skroch-Angel P, Claassen CJ, Look MP, Ponta H, Van Putten WL, Herrlich P, Henzen-Logmans SC.

Int J Cancer. 1999 Jun 21;84(3):209-15.

14.

Genetic alterations in ovarian borderline tumours and ovarian carcinomas.

Schuyer M, Henzen-Logmans SC, van der Burg ME, Fieret JH, Derksen C, Look MP, Meijer-van Gelder ME, Klijn JG, Foekens JA, Berns EM.

Eur J Obstet Gynecol Reprod Biol. 1999 Feb;82(2):147-50. No abstract available.

PMID:
10206406
15.
16.

Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures.

van Roozendaal CE, Gillis AJ, Klijn JG, van Ooijen B, Claassen CJ, Eggermont AM, Henzen-Logmans SC, Oosterhuis JW, Foekens JA, Looijenga LH.

FEBS Lett. 1998 Oct 16;437(1-2):107-11.

17.

High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands.

Schuyer M, Henzen-Logmans SC, van der Burg ME, Fieret EJ, Klijn JG, Foekens JA, Berns EM.

Int J Cancer. 1998 May 4;76(3):299-303.

18.

The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck.

Takes RP, Righi P, Meeuwis CA, Manni JJ, Knegt P, Marres HA, Spoelstra HA, de Boer MF, van der Mey AG, Bruaset I, Ball V, Weisberger E, Radpour S, Kruyt RH, Joosten FB, Laméris JS, van Oostayen JA, Kopecky K, Caldemeyer K, Henzen-Logmans SC, Wiersma-van Tilburg JM, Bosman FT, van Krieken JH, Hermans J, Baatenburg de Jong RJ.

Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1027-32.

PMID:
9539556
19.

Prognostic significance of cathepsins B and L in primary human breast cancer.

Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

J Clin Oncol. 1998 Mar;16(3):1013-21.

PMID:
9508185
20.
21.

Immunocytochemical staining of effusions; an external quality control study in The Netherlands.

Kuenen-Boumeester V, De Bruijn EM, Henzen-Logmans SC.

Cytopathology. 1997 Aug;8(4):248-55.

PMID:
9252742
22.

Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method.

Bonnema J, van Geel AN, van Ooijen B, Mali SP, Tjiam SL, Henzen-Logmans SC, Schmitz PI, Wiggers T.

World J Surg. 1997 Mar-Apr;21(3):270-4.

PMID:
9015169
23.

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.

Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA.

Br J Cancer. 1997;76(4):486-93.

24.

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.

van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL, Klijn JG, Foekens JA.

Int J Cancer. 1996 Dec 20;69(6):475-9.

25.

Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.

Schuyer M, van Staveren IL, Klijn JG, vd Burg ME, Stoter G, Henzen-Logmans SC, Foekens JA, Berns EM.

Br J Cancer. 1996 Oct;74(7):1069-73.

26.

The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.

Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, Henzen-Logmans SC.

Eur J Cancer. 1996 Aug;32A(9):1560-5.

PMID:
8911118
27.

Quality control of immunocytochemical staining of effusions using a standardized method of cell processing.

Kuenen-Boumeester V, van Loenen P, de Bruijn EM, Henzen-Logmans SC.

Acta Cytol. 1996 May-Jun;40(3):475-9.

PMID:
8669182
28.

Regional metastasis in head and neck squamous cell carcinoma: revised value of US with US-guided FNAB.

Takes RP, Knegt P, Manni JJ, Meeuwis CA, Marres HA, Spoelstra HA, de Boer MF, Bruaset I, van Oostayen JA, Laméris JS, Kruyt RH, Joosten FB, van Krieken JH, Bosman FT, Henzen-Logmans SC, Wiersma-van Tilburg JM, Hermans J, Baatenburg de Jong RJ.

Radiology. 1996 Mar;198(3):819-23. Erratum in: Radiology 1997 Jan;202(1):285.

PMID:
8628877
29.

Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources.

van Roozendaal KE, Klijn JG, van Ooijen B, Claassen C, Eggermont AM, Henzen-Logmans SC, Foekens JA.

Int J Cancer. 1996 Jan 3;65(1):120-5.

30.

Systemic and anti-neuronal auto-antibodies in patients with paraneoplastic neurological disease.

Moll JW, Hooijkaas H, van Goorbergh BC, Roos LG, Henzen-Logmans SC, Vecht CJ.

J Neurol. 1996 Jan;243(1):51-6.

PMID:
8869387
31.

The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary.

van der Gaast A, Verwij J, Planting AS, Stoter G, Henzen-Logmans SC.

J Cancer Res Clin Oncol. 1996;122(3):181-85.

PMID:
8601568
32.

Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer.

van Agthoven T, Timmermans M, Dorssers LC, Henzen-Logmans SC.

Int J Cancer. 1995 Dec 11;63(6):790-3.

PMID:
8847135
33.

Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence.

Abeln EC, Kuipers-Dijkshoorn NJ, Berns EM, Henzen-Logmans SC, Fleuren GJ, Cornelisse CJ.

Br J Cancer. 1995 Nov;72(5):1330-6.

34.

Expression of the gene encoding growth hormone in the human mammary gland.

Mol JA, Henzen-Logmans SC, Hageman P, Misdorp W, Blankenstein MA, Rijnberk A.

J Clin Endocrinol Metab. 1995 Oct;80(10):3094-6.

PMID:
7559904
35.
36.

Transforming growth factor beta secretion from primary breast cancer fibroblasts.

van Roozendaal CE, Klijn JG, van Ooijen B, Claassen C, Eggermont AM, Henzen-Logmans SC, Foekens JA.

Mol Cell Endocrinol. 1995 Apr 28;111(1):1-6.

PMID:
7649348
37.

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication.

Kruit WH, Punt KJ, Goey SH, de Mulder PH, van Hoogenhuyze DC, Henzen-Logmans SC, Stoter G.

Cancer. 1994 Nov 15;74(10):2850-6.

PMID:
7954247
38.

Quantification of area percentage of immunohistochemical staining by true color image analysis with application of fixed thresholds.

Willemse F, Nap M, Henzen-Logmans SC, Eggink HF.

Anal Quant Cytol Histol. 1994 Oct;16(5):357-64.

PMID:
7530958
39.

Leucocytoclastic vasculitis as presenting feature of primary Sjögren's syndrome.

Markusse HM, Schoonbrood M, Oudkerk M, Henzen-Logmans SC.

Clin Rheumatol. 1994 Jun;13(2):269-72.

PMID:
8088072
40.
41.

Anti-neuronal antibodies in Sjögren's syndrome and in paraneoplastic neurological disease.

Moll JW, Markusse HM, Henzen-Logmans SC, Vecht CJ.

Lancet. 1994 May 21;343(8908):1299. No abstract available.

PMID:
7910309
42.

Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D.

Henzen-Logmans SC, Fieret EJ, Berns EM, van der Burg ME, Klijn JG, Foekens JA.

Int J Cancer. 1994 May 15;57(4):468-72.

PMID:
8181851
43.

Antineuronal antibodies in patients with neurologic complications of primary Sjögren's syndrome.

Moll JW, Markusse HM, Pijnenburg JJ, Vecht CJ, Henzen-Logmans SC.

Neurology. 1993 Dec;43(12):2574-81.

PMID:
8255460
44.

Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.

van der Gaast A, Henzen-Logmans SC, Planting AS, Stoter G, Verweij J.

Ann Oncol. 1993 Nov;4(9):789-90.

45.

Axillary nodal metastases from an occult primary consistent with breast carcinoma.

van Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PC.

Br J Surg. 1993 Oct;80(10):1299-300.

PMID:
8242304
46.

[Endometriosis of the rectum].

van Ooijen B, Henzen-Logmans SC, Wiggers T.

Ned Tijdschr Geneeskd. 1993 May 29;137(22):1102-5. Dutch.

PMID:
8510787
47.

Angiosarcoma of the breast following lumpectomy, axillary lymph node dissection, and radiotherapy for primary breast cancer: three case reports and a review of the literature.

Wijnmaalen A, van Ooijen B, van Geel BN, Henzen-Logmans SC, Treurniet-Donker AD.

Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):135-9. Review.

PMID:
8387065
48.

Cervical cancer metastasising to the breast: report of two cases.

Van Ooijen B, Slot A, Henzen-Logmans SC, Wiggers T.

Eur J Surg. 1993 Feb;159(2):125-6. No abstract available.

PMID:
8098627
49.

Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration.

Moll JW, Henzen-Logmans SC, Van der Meché FG, Vecht CH.

J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):112. No abstract available.

50.

The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study.

van der Burg ME, Henzen-Logmans SC, Foekens JA, Berns EM, Rodenburg CJ, van Putten WL, Klijn JG.

Eur J Cancer. 1993;29A(14):1951-7.

PMID:
8280488

Supplemental Content

Loading ...
Support Center